Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection

Background: The estimated economic cost of Clostridioides difficile infection (CDI) is $5.4 billion annually, primarily attributed to acute-care costs. We previously reported data from ECOSPOR III that SER-109, an investigational oral microbiome therapeutic, was superior to placebo in reducing recur...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Stuart, Louie, Thomas, Berenson, Charles, Amin, Alpesh, Lombardi, David, Pham, Sissi, Huang, Shirley, Wang, Elaine, Hasson, Brooke, McGovern, Barbara, Von Moltke, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
C. Difficile
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614905/
http://dx.doi.org/10.1017/ash.2022.196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614905/
http://dx.doi.org/10.1017/ash.2022.196

Ejemplares similares